Product Information
PERSERIS ER 120 MG SYRINGE KIT is a brand product labeled by Indivior Inc., priced at $2764.7050 per EA under NDC 12496012001. Its NADAC has been published 172 times since Jun 21, 2023.
FDA first approved this application on Jul 27, 2018.
The High Outlier badge above means this manufacturer's average price in the Risperidone market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Indivior Inc.NDC
12496012001
Classification
Brand
Dosage Form
KIT
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Approval Type
New Drug (NDA)
FDA Application
NDA210655FDA Approved
7/27/2018
On Market Since
11/9/2018
Price Statistics
The NADAC for PERSERIS ER 120 MG SYRINGE KIT has been published 172 times since Jun 21, 2023, and over the history we have for it it has risen 4.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2764.7050 per EA |
|---|---|
| All-time high | $2786.2219 (Feb 11, 2026) |
| All-time low | $2639.3240 (Jun 21, 2023) |
| 52-week high | $2786.2219 |
| 52-week low | $2761.2209 |
| Median price | $2767.1007 |
| Average price | $2747.9628 |
| Largest weekly change | +5.0% (Jan 3, 2024) |
| Weeks tracked | 172 |
| Tracking since | Jun 21, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 87% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Indivior Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Risperidone market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PERSERIS ER 120 MG SYRINGE KIT?
The current National Average Drug Acquisition Cost (NADAC) for PERSERIS ER 120 MG SYRINGE KIT, manufactured by Indivior Inc., is $2764.7050 per EA (NDC 12496012001), effective Sep 30, 2026.
How has the price of PERSERIS ER 120 MG SYRINGE KIT changed over time?
Over the history we have for it, the NADAC for PERSERIS ER 120 MG SYRINGE KIT has risen 4.8%. It has been tracked across 172 weekly CMS publications since Jun 21, 2023.
What are the highest and lowest recorded NADAC prices for PERSERIS ER 120 MG SYRINGE KIT?
Since Jun 21, 2023, the NADAC for PERSERIS ER 120 MG SYRINGE KIT has ranged from a low of $2639.3240 (Jun 21, 2023) to a high of $2786.2219 (Feb 11, 2026), with a median of $2767.1007 per EA.
Are there cheaper alternatives to PERSERIS ER 120 MG SYRINGE KIT?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RISPERIDONE ER 25 MG VIAL, is $355.2316 per EA — about 87% below PERSERIS ER 120 MG SYRINGE KIT.
Who manufactures PERSERIS ER 120 MG SYRINGE KIT?
PERSERIS ER 120 MG SYRINGE KIT (NDC 12496012001) is labeled by Indivior Inc., and CMS classifies it as a brand product.